I'd suggest also that those patients that didn't complete the protocol may have dropped out and self selected because they weren't experiencing any benefit that would motivate them to continue the treatment to the end of the study. Maybe that also happened in the previous trial which is why the Lucentis response was so good - essentially the patients self selected the best responders to artificially elevate the efficacy.
Ann: Opthea Reports Positive Ph2a Trial Results of OPT-302 in DME, page-62
Add OPT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
86.8¢ |
Change
-0.028(3.07%) |
Mkt cap ! $1.064B | |||
| Open | High | Low | Value | Volume |
| 88.5¢ | 88.5¢ | 85.8¢ | $1.331M | 1.533M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 20 | 24990 | 86.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 87.0¢ | 21462 | 13 |
View Market Depth
| Last trade - 11.29am 08/10/2024 (20 minute delay) ? |
| OPT (ASX) Chart |